U.S. Entertainment Stock News

If you are wondering whether Amneal Pharmaceuticals' current share price reflects its true worth, the recent returns give you plenty to think about. The stock last closed at US$12.80, with a 2.6% return over 7 days, a 4.1% decline over 30 days, a 1.1% return year to date, and a very strong 83.6% return over the past year, alongside a very large gain over 3 years and a 116.9% return over 5 years. Recent price moves have put more attention on how Amneal Pharmaceuticals is being valued and what...

Investors may be wondering whether Travelers Companies, at around its recent US$303.23 close, still offers value or if most of the potential upside has already been priced in. The stock has posted returns of 3.1% over the last 7 days, 0.3% over 30 days, 6.3% year to date and 25.6% over 1 year, with longer-term returns of 85.0% over 3 years and 116.8% over 5 years. Recent coverage has focused on Travelers Companies as a large US insurer and how investors are reassessing established insurance...

Why Zoetis stock is back in focus after fresh activism and recent earnings Zoetis (ZTS) is drawing attention after reporting organic revenue and adjusted net income growth. The company is also facing a new shareholder rights proposal that management is urging investors to vote against at the upcoming annual meeting. See our latest analysis for Zoetis. The fresh activism around shareholder rights arrives after a weaker run for investors, with a 1-year total shareholder return of 17.19% and a...

In early April 2026, Ground Control announced a partnership with Viavi Solutions to integrate Viavi’s Secure µPNT STL-1000 receiver into the RockFLEET Assured maritime asset tracking and assured navigation system for GNSS-denied environments. This collaboration highlights Viavi’s role in providing resilient, secure timing and navigation technology for critical missions where traditional satellite signals may be disrupted. We’ll now examine how this assured navigation partnership, focused on...

Byrna Technologies (BYRN) has just opened its Q1 2026 earnings season narrative following a Q4 2025 print that showed total revenue of US$35.2 million and basic EPS of US$0.15, with trailing twelve month revenue at US$118.1 million and basic EPS of US$0.43. Over recent quarters the company has seen revenue move from US$27.9 million in Q4 2024 to US$35.2 million in Q4 2025, while basic EPS shifted from US$0.43 to US$0.15. This sets up a results story where investors are likely to focus on how...

In recent weeks, Goldman Sachs Group has issued a series of new fixed-income securities across multiple currencies and maturities, while its private credit fund met elevated first-quarter redemption requests without imposing withdrawal limits, highlighting resilient funding access and liquidity management. At the same time, analysts and market data point to robust first-quarter trading and investment banking activity at Goldman Sachs, with its institutional-heavy private credit platform...

For investors wondering whether Coinbase Global at around US$169 per share still offers value or now reflects most of the story, this article walks through what the current price may be implying. The stock has recently been volatile, with returns of a 1.4% decline over the last 7 days, a 14.0% decline over 30 days, a 28.5% decline year to date, a 0.3% decline over 1 year and a 145.3% gain over 3 years, compared with a 47.6% decline over 5 years. Recent headlines have continued to focus on...

In recent months, several law firms have launched securities fraud class action lawsuits against monday.com, alleging that between September 17, 2025 and February 6, 2026 the company misled investors about decelerating customer growth, weaker expansion within existing accounts, and its financial outlook. The lawsuits center on claims that monday.com’s public statements about revenue growth, performance marketing, and long-term targets were materially inconsistent with internal trends,...

Riot Platforms (RIOT) is in the spotlight after selling roughly US$200 million of Bitcoin to fund a planned 112 megawatt AI data center. This move marks a clear shift in how the company uses its mining driven balance sheet. See our latest analysis for Riot Platforms. The recent plan to channel roughly US$200 million of Bitcoin sales into a 112 megawatt AI data center comes on top of a 1 day share price return of 3.56% and a 7 day share price return of 29.73%. The 1 year total shareholder...

ASGN stock performance snapshot after recent weakness ASGN (ASGN) has been under pressure recently, with the share price down about 9% over the past week and showing declines over the past month and past 3 months as well. See our latest analysis for ASGN. At the latest share price of $37.28, ASGN’s 1 year total shareholder return of a 37.16% decline and 5 year total shareholder return of a 65.44% decline point to fading momentum, with recent weakness adding to an already prolonged...

Novavax recently named Dr. Robert Walker as Executive Vice President and Head of R&D, while activist investor Shah Capital renewed its campaign to oppose board nominees, executive pay, and the current leadership’s approach to partnerships and costs. These moves highlight a growing tension between an R&D-focused leadership reshuffle and an activist push for a leaner organization and potentially different corporate direction. Against this backdrop of sharper activist pressure on Novavax’s...

Anthropic has introduced Claude Mythos, an advanced AI model that can autonomously search for zero day cybersecurity vulnerabilities. The launch raises fresh questions for identity security providers such as Okta, including how traditional defenses will hold up as AI driven threat discovery accelerates. Investors in NasdaqGS:OKTA are watching for how the company responds to this shift in attack capabilities across the wider security sector. Okta, trading at $67.76, sits at the center of...

On 31 March 2026, Niagen Bioscience, Inc. announced it had engaged OneSpaWorld to offer pharmaceutical-grade Niagen IV treatments at more than 80 Medi-Spa clinics onboard high-end cruise ships, supplied through FDA-registered Wells Pharma of Houston and rolled out in line with ship-specific regulatory requirements. This partnership broadens OneSpaWorld’s higher-end medi-spa and longevity services, integrating a new clinical-grade IV offering into its cruise wellness footprint and deepening...

Navitas Semiconductor recently unveiled an AI-focused power delivery board at NVIDIA’s GTC 2026, a move that has sharpened attention on its role in next-generation data center infrastructure. The subsequent profit-taking, sector-wide semiconductor weakness, and questions around valuation and a new CFO highlight how quickly sentiment can shift as Navitas leans further into AI infrastructure. We’ll now examine how concerns about valuation and execution around Navitas’s AI push may influence...

If you are wondering whether Century Aluminum at around US$66.30 is still offering value or has already run too far ahead, the numbers give you a lot to think about. The share price has seen sharp moves recently, with returns of 6.0% over 7 days, 23.8% over 30 days, 61.9% year to date, 352.8% over 1 year and a very large gain over 3 years relative to its starting level. These moves have put Century Aluminum firmly on investors' radars, with attention now firmly on whether the current price...

Resources Connection (RGP) has reported Q3 2026 revenue of US$107.9 million alongside a basic EPS loss of US$0.28, with trailing 12 month EPS at a loss of US$2.94 on revenue of US$485.2 million. The company has seen quarterly revenue move from US$145.6 million in Q2 2025 to US$129.4 million in Q3 2025 and then to US$107.9 million in Q3 2026. Over the same period, quarterly EPS moved from a loss of US$2.08 in Q2 2025 to a loss of US$1.34 in Q3 2025 and then to a loss of US$0.28 in Q3 2026,...

Pure Cycle (PCYO) has reported its Q2 2026 numbers, with total revenue of US$5.2 million and net income of US$1.1 million. This translates to basic EPS of US$0.05, compared with a current share price of US$11.85. Over recent quarters, the company’s revenue increased from US$4.0 million in Q2 2025 to US$5.2 million in Q2 2026, while basic EPS moved from US$0.03 to US$0.05 as net income rose from US$0.8 million to US$1.1 million. This sits against a backdrop of a 45.8% net profit margin over...

S&P Global (SPGI) has launched its first Private Markets Performance Analytics datasets with Cambridge Associates and Mercer, giving investors new standardized data on private credit and real assets to support portfolio decisions. See our latest analysis for S&P Global. Despite launching new private markets datasets and appointing a new Chief Technology and Transformation Officer, S&P Global’s share price return has been weak recently. The 90 day share price decline of 21.7%, alongside the 3...

A series of recent product updates has put Fiserv (FISV) in focus, as new integrations for its Clover platform and Pay by Bank offering highlight how the company is working more deeply with key clients. See our latest analysis for Fiserv. Despite the fresh client wins and product integrations, the share price has slipped to US$56.41, with a 30 day share price return of 5.11% and a 90 day share price return of 19.24%. The 1 year total shareholder return of 72.40% and 5 year total shareholder...

If you are wondering whether Capital Southwest at around US$22.67 is priced for opportunity or already reflects the story you are paying for, this breakdown will help you frame what the current share price might be implying. Over shorter periods, the stock has returned 1.3% over 7 days and 3.1% over 30 days, with returns of 1.7% year to date and 34.6% over 1 year. The 3 year and 5 year figures sit at 74.0% and 69.2% respectively. Recent news flow around Capital Southwest has largely focused...

If you are considering Virtu Financial at around US$49.66 and wondering whether it offers value or requires paying a premium for quality, this breakdown can help you clarify that question before committing fresh capital. The stock has posted returns of 7.4% over 7 days, 21.0% over 30 days, 52.3% year to date and 43.1% over 1 year, with a 3 year return of 188.3% and a 5 year return of 91.7%. These figures naturally raise questions about how the current price compares with the company’s...

In early April 2026, Ollie’s Bargain Outlet Holdings reported insider share sales by Executive Chairman John Swygert under a pre-arranged trading plan, alongside the upcoming retirement of Senior Vice President and General Merchandise Manager Kevin McLain and his planned replacement by Shane Thornton. These leadership changes and insider transactions, combined with shifting institutional holdings and differing analyst views, have sharpened investor focus on how Ollie’s is being run and...

Nuvalent, Inc. recently submitted a New Drug Application to the U.S. FDA for neladalkib, an investigational ALK-selective inhibitor for TKI pre-treated advanced ALK-positive non-small cell lung cancer, supported by Phase 1/2 ALKOVE-1 trial data showing encouraging activity and a generally well-tolerated safety profile. The filing is bolstered by neladalkib’s breakthrough therapy and orphan drug designations, underscoring its potential role in addressing difficult-to-treat ALK-positive NSCLC...

Investors may be wondering whether Blue Owl Capital's current share price reflects its underlying value, or if the recent pullback has gone too far. The stock last closed at US$8.28, with a 3.4% decline over 7 days, a 12.5% decline over 30 days, and a 45.9% decline year to date. This adds up to a 49.0% decline over the past year and a 12.8% decline over 3 years, while the 5-year return sits at 1.2%. Recent coverage of Blue Owl Capital has focused on its position within the wider capital...